Transforming Gynecologic Care
Through AI-powered Diagnostics

We are revolutionizing women’s health through innovative testing options, leveraging a data-driven approach to empower patients and healthcare providers in achieving optimal gynecologic care.

Advancing Women’s Health Starts
with Groundbreaking Research

We combine cutting-edge technology with clinical expertise to develop innovative testing solutions. Our research efforts are dedicated to improving women's lives through earlier risk assessment, more accurate diagnoses, and personalized care strategies through rigorous scientific investigation.

+
peer-reviewed publications
+
Years of experience leveraging AI to develop Aspira's products, offering personalized risk assessment scores
+
tests ordered by healthcare providers

OvaSuiteSM: A Comprehensive Portfolio
of Non-invasive Ovarian Care Solutions

Aspira_OVAWatch(R) logo 1

Planned for Clinical Management

  • For adnexal masses initially evaluated as indeterminate or benign
  • Negative Predictive Value of over 99%1
  • Longitudinal monitoring feature to help providers track risk over time
Ova1 plus

Planned for Surgical Management

  • For adnexal masses that are planned for surgery
  • Ova1® has a sensitivity of over 96% with clinical assessment2
  • Biomarkers (including CA-125), menopausal status, and ultrasound for a personalized risk score

Ova1Plus is a reflex process: Ova1® is performed3 first. If an intermediate risk is detected, Overa® is automatically performed.

 A recent study indicates that using OvaWatch could have led to a potential3:

%

overall reduction in avoidable adnexal mass surgeries 

%

reduction of surgical referrals among asymptomatic patients

%

reduction of surgical referrals among premenopausal patients

 

Ova1 Showed Superior Malignancy Risk Detection in Cases Where CA-125 was Uninformative4

Across All Stages

According to a peer-reviewed study, Ova1 showed most cases ovarian cancer risk that were missed by CA-125

Stage I and II

Ova1 detected
%
of early-stage malignancy risk missed by CA-125

Premenopausal

Ova1 identified
%
(20/39) of premenopausal cancers for which CA-125 failed to detect malignancy

Postmenopausal

Ova1 identified
%
(22/37) of postmenopausal cancers for which CA-125 failed to detect malignancy

I'm a Patient or Individual

Take control of your gynecologic health.

I'm a Provider

Improve diagnostic accuracy of ovarian cancer at your practice.

Learn More About Aspira

Learn More About Aspira

Ready to connect with us?

PRECAUTION:
OVAWATCH IS INTENDED FOR USE AS A NON-INVASIVE TEST TO ASSESS THE RISK OF OVARIAN CANCER FOR WOMEN WITH ADNEXAL MASSES, EVALUATED BY INITIAL CLINICAL ASSESSMENT (ICA) AS INDETERMINATE OR BENIGN. IN CONJUNCTION WITH IMAGING (ULTRASOUND AND/OR CT) AND CLINICAL ASSESSMENT, THIS TEST WILL SUPPORT PHYSICIANS IN MAKING INFORMED CLINICAL DECISIONS IN THE MANAGEMENT OF WOMEN WITH ADNEXAL MASSES. THE TEST IS NOT INTENDED AS A SCREENING TEST OR A STAND-ALONE DIAGNOSTIC ASSAY.

OVA1 AND OVERA SHOULD NOT BE USED WITHOUT AN INDEPENDENT CLINICAL AND IMAGING EVALUATION AND IS NOT INTENDED TO BE A SCREENING TEST OR TO DETERMINE WHETHER A PATIENT SHOULD PROCEED TO SURGERY. INCORRECT USE CARRIES THE RISK OF UNNECESSARY TESTING, SURGERY, AND/OR DELAYED DIAGNOSIS.

*In cases of an intermediate Ova1® result, the FDA-cleared Overa® reflex is performed to increase specificity